Skip Navigation



eCAM Advance Access published online on November 26, 2009
eCAM, doi:10.1093/ecam/nep179
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ho, H.-Y.
Right arrow Articles by Lin, W.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, H.-Y.
Right arrow Articles by Lin, W.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Flemingia macrophylla Extract Ameliorates Experimental Osteoporosis in Ovariectomized Rats

Hui-Ya Ho1, Jin-Bin Wu1 and Wen-Chuan Lin2

1Graduate Institute of Pharmaceutical Chemistry, School of Pharmacy and 2School of Medicine, Graduate Institute of Basic Medical Science and Tsuzuki Institute for Traditional Medicine, China Medical University, Taichung, Taiwan

Flemingia macrophylla (Leguminosae), a native plant of Taiwan, is used as folk medicine. An in vitro study showed that a 75% ethanolic extract of F. macrophylla (FME) inhibited osteoclast differentiation of cultured rat bone marrow cells, and the active component, lespedezaflavanone A (LDF-A), was isolated. It was found that oral administration of FME for 13 weeks suppressed bone loss in ovariectomized rats, an experimental model of osteoporosis. In addition, FME decreased urinary deoxypyridinoline concentrations but did not inhibit serum alkaline phosphatase activities, indicating that it ameliorated bone loss via inhibition of bone resorption. These results suggest that FME may represent a useful remedy for the treatment of bone resorption diseases, such as osteoporosis. In addition, LDF-A could be used as a marker compound to control the quality of FME.

Keywords: Flemingia macrophylla – lespedezaflavanone A – osteoclast – osteoporosis

For reprints and all correspondence: Wen-Chuan Lin, Department of Pharmacology, China Medical University, 91 Hsueh Shih Road, Taichung, Taiwan, Republic of China. Tel: +886-4-22053366 (Ext. 2229); Fax: +886 4 22053764; E-mail: wclin{at}mail.cmu.edu.tw

Received June 16, 2009; accepted October 6, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.